Seattle-area — Ekhbary News Agency
A Kirkland, Washington-based biotechnology firm, spearheaded by former Athira Pharma CEO Leen Kawas, has successfully closed a $35 million Series A funding round. This substantial capital injection is specifically allocated to accelerate the development of a novel drug designed to combat hepatitis D.
Strategic Investment Fuels Drug Development
The funding underscores robust investor confidence in innovative biopharmaceutical ventures, particularly those addressing challenging viral diseases. Kawas, for what it's worth, brings a wealth of experience from her previous leadership role, a factor likely influencing this significant backing. Securing such a sum early on is crucial for propelling the company's ambitious research agenda forward, aiming for potential therapeutic breakthroughs.
Read Also
- PlayStation to Pay $7.85 Million in Class-Action Lawsuit Settlement
- Gal Gadot Reveals Confusion Over Wonder Woman 3 Cancellation
- AMC Theaters Launches Leawood Films, Eyes Independent Movie Distribution
- Duane Davis Convicted of Tupac Shakur's 1996 Murder After Decades-Long Investigation
- IGN Australia, Chupa Chups Announce Retro Gaming Fun House Event
